Industry Research Reports
Home > Reports > Chemical & Material > Global Bifidobacterium Longum Subsp. Infantis M-63 Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Bifidobacterium Longum Subsp. Infantis M-63 Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Chemical & Material
Published Date: 2025-08-05
Pages: 190 Pages
Report ld: 4855662
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Bifidobacterium Longum Subsp. Infantis M-63 Market Size(US$)
CAGR 2025-2031
6.2%
Market Size,2031
USD 67.7
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 47.2 million
Market Forecast in 2031(Value)
US$ 67.7 million
CAGR
6.2%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Bifidobacterium Longum Subsp. Infantis M-63 market is projected to grow from US$ 44.7 million in 2024 to US$ 67.7 million by 2031, at a CAGR of 6.2% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Bifidobacterium Longum Subsp. Infantis M-63 is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
From a downstream perspective, Food Additives accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Bifidobacterium Longum Subsp. Infantis M-63 leading manufacturers including Mitushi Biopharma, Fengchen Group, Jiangsu Wecare Biotechnology Co., Ltd., Shenzhen Lefu Biotechnology Co., Ltd., Hebei Hongtao Bioengineering Co., Ltd., Shandong Junle Biotechnology Co., Ltd., Shandong Xinxiong Biotechnology Co., Ltd., Newgen Biotech, Pharm-Rx, Rajvi Enterprise, etc., dominate supply; the top five capture approximately % of global revenue, with Mitushi Biopharma leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Bifidobacterium Longum Subsp. Infantis M-63 market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Mitushi Biopharma
- Fengchen Group
- Jiangsu Wecare Biotechnology Co., Ltd.
- Shenzhen Lefu Biotechnology Co., Ltd.
- Hebei Hongtao Bioengineering Co., Ltd.
- Shandong Junle Biotechnology Co., Ltd.
- Shandong Xinxiong Biotechnology Co., Ltd.
- Newgen Biotech
- Pharm-Rx
- Rajvi Enterprise
- Shandong Pingao Pharmaceutical Co., Ltd.
- Shaanxi Chenming Biotechnology Co., Ltd.
- Xi'an Minglang Biotechnology Co., Ltd.
- Jiahe Biotechnology (Shanxi) Co., Ltd.
- Shaanxi Ruimao Biotechnology Co., Ltd.
- Shaanxi Baohe Biotechnology Co., Ltd.
- Shaanxi Lesent Biotechnology Co., Ltd.
- Shaanxi Shuoyang Biotechnology Co., Ltd.
- Shaanxi Mufan Biotechnology Co., Ltd.
- Xi'an An'Drong Biomedical Technology Co., Ltd.
- Shaanxi Guanchen Biotechnology Co., Ltd.
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- 0-50 billion CFU/g
- 50-100 billion CFU/g
- ＞100 billion CFU/g
Segment by Application
- Food Additives
- Medicines and Supplements
- Feed Additives
- Others
CHAPTER OUTLINE
Chapter 1: Defines the Bifidobacterium Longum Subsp. Infantis M-63 study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.
Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.
Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Bifidobacterium Longum Subsp. Infantis M-63: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Bifidobacterium Longum Subsp. Infantis M-63 Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 0-50 billion CFU/g
1.2.3 50-100 billion CFU/g
1.2.4 ＞100 billion CFU/g
1.3 Market Segmentation by Application
1.3.1 Global Bifidobacterium Longum Subsp. Infantis M-63 Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Food Additives
1.3.3 Medicines and Supplements
1.3.4 Feed Additives
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue Estimates and Forecasts 2020-2031
2.2 Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Estimates and Forecasts 2020-2031
2.4 Global Bifidobacterium Longum Subsp. Infantis M-63 Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Global Production Analysis
3.1 Global Bifidobacterium Longum Subsp. Infantis M-63 Production Capacity and Utilization Rates (2020–2031)
3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)
3.3 Regional Production Dynamics
3.3.1 Historic Production by Region (2020-2025)
3.3.2 Forecasted Production by Region (2026-2031)
3.3.3 Production Market Share by Region (2020-2031)
3.3.4 Regulatory and Trade Policy Impact on Production
3.3.5 Production Capacity Enablers and Constraints
3.4 Key Regional Production Hubs
3.4.1 North America
3.4.2 Europe
3.4.3 China
3.4.4 Japan
4 Competition by Manufacturers
4.1 Global Bifidobacterium Longum Subsp. Infantis M-63 Sales by Manufacturers
4.1.1 Global Sales Volume by Manufacturers (2020-2025)
4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
4.2 Global Bifidobacterium Longum Subsp. Infantis M-63 Manufacturer Revenue Rankings and Tiers
4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
4.3 Manufacturer Profitability Profiles and Pricing Strategies
4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
4.3.2 Manufacturer-Level Price Trends (2020-2025)
4.4 Key Manufacturers Manufacturing Base and Headquarters
4.5 Main Product Type Market Size by Manufacturers
4.5.1 0-50 billion CFU/g Market Size by Manufacturers
4.5.2 50-100 billion CFU/g Market Size by Manufacturers
4.5.3 ＞100 billion CFU/g Market Size by Manufacturers
4.6 Global Bifidobacterium Longum Subsp. Infantis M-63 Market Concentration and Dynamics
4.6.1 Global Market Concentration (CR5 and HHI)
4.6.2 Entrant/Exit Impact Analysis
4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
5 Global Product Segmentation Analysis
5.1 Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Performance by Type
5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
5.1.2 Global Sales Market Share by Type (2020-2031)
5.2 Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue Trends by Type
5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
5.2.2 Global Revenue Market Share by Type (2020-2031)
5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
5.4 Product Technology Differentiation
5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
5.5.1 High-Growth Niches and Adoption Drivers
5.5.2 Profitability Hotspots and Cost Drivers
5.5.3 Substitution Threats
6 Global Downstream Application Analysis
6.1 Global Bifidobacterium Longum Subsp. Infantis M-63 Sales by Application
6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
6.1.2 Global Sales Market Share by Application (2020-2031)
6.1.3 High-Growth Application Identification
6.1.4 Emerging Application Case Studies
6.2 Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue by Application
6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
6.2.2 Revenue Market Share by Application (2020-2031)
6.3 Global Pricing Dynamics by Application (2020-2031)
6.4 Downstream Customer Analysis
6.4.1 Top Customers by Region
6.4.2 Top Customers by Application
7 North America
7.1 North America Sales Volume and Revenue (2020-2031)
7.2 North America Key Manufacturers Sales Revenue in 2024
7.3 North America Bifidobacterium Longum Subsp. Infantis M-63 Sales and Revenue by Type (2020-2031)
7.4 North America Bifidobacterium Longum Subsp. Infantis M-63 Sales and Revenue by Application (2020-2031)
7.5 North America Growth Accelerators and Market Barriers
7.6 North America Bifidobacterium Longum Subsp. Infantis M-63 Market Size by Country
7.6.1 North America Revenue by Country
7.6.2 North America Sales Trends by Country
7.6.3 US
7.6.4 Canada
7.6.5 Mexico
8 Europe
8.1 Europe Sales Volume and Revenue (2020-2031)
8.2 Europe Key Manufacturers Sales Revenue in 2024
8.3 Europe Bifidobacterium Longum Subsp. Infantis M-63 Sales and Revenue by Type (2020-2031)
8.4 Europe Bifidobacterium Longum Subsp. Infantis M-63 Sales and Revenue by Application (2020-2031)
8.5 Europe Growth Accelerators and Market Barriers
8.6 Europe Bifidobacterium Longum Subsp. Infantis M-63 Market Size by Country
8.6.1 Europe Revenue by Country
8.6.2 Europe Sales Trends by Country
8.6.3 Germany
8.6.4 France
8.6.5 U.K.
8.6.6 Italy
8.6.7 Russia
9 Asia-Pacific
9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
9.3 Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Sales and Revenue by Type (2020-2031)
9.4 Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Sales and Revenue by Application (2020-2031)
9.5 Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Market Size by Region
9.5.1 Asia-Pacific Revenue by Region
9.5.2 Asia-Pacific Sales Trends by Region
9.6 Asia-Pacific Growth Accelerators and Market Barriers
9.7 Southeast Asia
9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand
9.8 China
9.9 Japan
9.10 South Korea
9.11 China Taiwan
9.12 India
10 Central and South America
10.1 Central and South America Sales Volume and Revenue (2020-2031)
10.2 Central and South America Key Manufacturers Sales Revenue in 2024
10.3 Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Sales and Revenue by Type (2020-2031)
10.4 Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Sales and Revenue by Application (2020-2031)
10.5 Central and South America Investment Opportunities and Key Challenges
10.6 Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Market Size by Country
10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 Brazil
10.6.3 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
11.3 Middle East and Africa Bifidobacterium Longum Subsp. Infantis M-63 Sales and Revenue by Type (2020-2031)
11.4 Middle East and Africa Bifidobacterium Longum Subsp. Infantis M-63 Sales and Revenue by Application (2020-2031)
11.5 Middle East and Africa Investment Opportunities and Key Challenges
11.6 Middle East and Africa Bifidobacterium Longum Subsp. Infantis M-63 Market Size by Country
11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
11.6.2 GCC Countries
11.6.3 Turkey
11.6.4 Egypt
11.6.5 South Africa
12 Corporate Profile
12.1 Mitushi Biopharma
12.1.1 Mitushi Biopharma Corporation Information
12.1.2 Mitushi Biopharma Business Overview
12.1.3 Mitushi Biopharma Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.1.4 Mitushi Biopharma Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.1.5 Mitushi Biopharma Bifidobacterium Longum Subsp. Infantis M-63 Sales by Product in 2024
12.1.6 Mitushi Biopharma Bifidobacterium Longum Subsp. Infantis M-63 Sales by Application in 2024
12.1.7 Mitushi Biopharma Bifidobacterium Longum Subsp. Infantis M-63 Sales by Geographic Area in 2024
12.1.8 Mitushi Biopharma Bifidobacterium Longum Subsp. Infantis M-63 SWOT Analysis
12.1.9 Mitushi Biopharma Recent Developments
12.2 Fengchen Group
12.2.1 Fengchen Group Corporation Information
12.2.2 Fengchen Group Business Overview
12.2.3 Fengchen Group Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.2.4 Fengchen Group Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.2.5 Fengchen Group Bifidobacterium Longum Subsp. Infantis M-63 Sales by Product in 2024
12.2.6 Fengchen Group Bifidobacterium Longum Subsp. Infantis M-63 Sales by Application in 2024
12.2.7 Fengchen Group Bifidobacterium Longum Subsp. Infantis M-63 Sales by Geographic Area in 2024
12.2.8 Fengchen Group Bifidobacterium Longum Subsp. Infantis M-63 SWOT Analysis
12.2.9 Fengchen Group Recent Developments
12.3 Jiangsu Wecare Biotechnology Co., Ltd.
12.3.1 Jiangsu Wecare Biotechnology Co., Ltd. Corporation Information
12.3.2 Jiangsu Wecare Biotechnology Co., Ltd. Business Overview
12.3.3 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.3.4 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.3.5 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Sales by Product in 2024
12.3.6 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Sales by Application in 2024
12.3.7 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Sales by Geographic Area in 2024
12.3.8 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 SWOT Analysis
12.3.9 Jiangsu Wecare Biotechnology Co., Ltd. Recent Developments
12.4 Shenzhen Lefu Biotechnology Co., Ltd.
12.4.1 Shenzhen Lefu Biotechnology Co., Ltd. Corporation Information
12.4.2 Shenzhen Lefu Biotechnology Co., Ltd. Business Overview
12.4.3 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.4.4 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.4.5 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Sales by Product in 2024
12.4.6 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Sales by Application in 2024
12.4.7 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Sales by Geographic Area in 2024
12.4.8 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 SWOT Analysis
12.4.9 Shenzhen Lefu Biotechnology Co., Ltd. Recent Developments
12.5 Hebei Hongtao Bioengineering Co., Ltd.
12.5.1 Hebei Hongtao Bioengineering Co., Ltd. Corporation Information
12.5.2 Hebei Hongtao Bioengineering Co., Ltd. Business Overview
12.5.3 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.5.4 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.5.5 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Sales by Product in 2024
12.5.6 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Sales by Application in 2024
12.5.7 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Sales by Geographic Area in 2024
12.5.8 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 SWOT Analysis
12.5.9 Hebei Hongtao Bioengineering Co., Ltd. Recent Developments
12.6 Shandong Junle Biotechnology Co., Ltd.
12.6.1 Shandong Junle Biotechnology Co., Ltd. Corporation Information
12.6.2 Shandong Junle Biotechnology Co., Ltd. Business Overview
12.6.3 Shandong Junle Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.6.4 Shandong Junle Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.6.5 Shandong Junle Biotechnology Co., Ltd. Recent Developments
12.7 Shandong Xinxiong Biotechnology Co., Ltd.
12.7.1 Shandong Xinxiong Biotechnology Co., Ltd. Corporation Information
12.7.2 Shandong Xinxiong Biotechnology Co., Ltd. Business Overview
12.7.3 Shandong Xinxiong Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.7.4 Shandong Xinxiong Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.7.5 Shandong Xinxiong Biotechnology Co., Ltd. Recent Developments
12.8 Newgen Biotech
12.8.1 Newgen Biotech Corporation Information
12.8.2 Newgen Biotech Business Overview
12.8.3 Newgen Biotech Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.8.4 Newgen Biotech Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.8.5 Newgen Biotech Recent Developments
12.9 Pharm-Rx
12.9.1 Pharm-Rx Corporation Information
12.9.2 Pharm-Rx Business Overview
12.9.3 Pharm-Rx Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.9.4 Pharm-Rx Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.9.5 Pharm-Rx Recent Developments
12.10 Rajvi Enterprise
12.10.1 Rajvi Enterprise Corporation Information
12.10.2 Rajvi Enterprise Business Overview
12.10.3 Rajvi Enterprise Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.10.4 Rajvi Enterprise Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.10.5 Rajvi Enterprise Recent Developments
12.11 Shandong Pingao Pharmaceutical Co., Ltd.
12.11.1 Shandong Pingao Pharmaceutical Co., Ltd. Corporation Information
12.11.2 Shandong Pingao Pharmaceutical Co., Ltd. Business Overview
12.11.3 Shandong Pingao Pharmaceutical Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.11.4 Shandong Pingao Pharmaceutical Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.11.5 Shandong Pingao Pharmaceutical Co., Ltd. Recent Developments
12.12 Shaanxi Chenming Biotechnology Co., Ltd.
12.12.1 Shaanxi Chenming Biotechnology Co., Ltd. Corporation Information
12.12.2 Shaanxi Chenming Biotechnology Co., Ltd. Business Overview
12.12.3 Shaanxi Chenming Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.12.4 Shaanxi Chenming Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.12.5 Shaanxi Chenming Biotechnology Co., Ltd. Recent Developments
12.13 Xi'an Minglang Biotechnology Co., Ltd.
12.13.1 Xi'an Minglang Biotechnology Co., Ltd. Corporation Information
12.13.2 Xi'an Minglang Biotechnology Co., Ltd. Business Overview
12.13.3 Xi'an Minglang Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.13.4 Xi'an Minglang Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.13.5 Xi'an Minglang Biotechnology Co., Ltd. Recent Developments
12.14 Jiahe Biotechnology (Shanxi) Co., Ltd.
12.14.1 Jiahe Biotechnology (Shanxi) Co., Ltd. Corporation Information
12.14.2 Jiahe Biotechnology (Shanxi) Co., Ltd. Business Overview
12.14.3 Jiahe Biotechnology (Shanxi) Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.14.4 Jiahe Biotechnology (Shanxi) Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.14.5 Jiahe Biotechnology (Shanxi) Co., Ltd. Recent Developments
12.15 Shaanxi Ruimao Biotechnology Co., Ltd.
12.15.1 Shaanxi Ruimao Biotechnology Co., Ltd. Corporation Information
12.15.2 Shaanxi Ruimao Biotechnology Co., Ltd. Business Overview
12.15.3 Shaanxi Ruimao Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.15.4 Shaanxi Ruimao Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.15.5 Shaanxi Ruimao Biotechnology Co., Ltd. Recent Developments
12.16 Shaanxi Baohe Biotechnology Co., Ltd.
12.16.1 Shaanxi Baohe Biotechnology Co., Ltd. Corporation Information
12.16.2 Shaanxi Baohe Biotechnology Co., Ltd. Business Overview
12.16.3 Shaanxi Baohe Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.16.4 Shaanxi Baohe Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.16.5 Shaanxi Baohe Biotechnology Co., Ltd. Recent Developments
12.17 Shaanxi Lesent Biotechnology Co., Ltd.
12.17.1 Shaanxi Lesent Biotechnology Co., Ltd. Corporation Information
12.17.2 Shaanxi Lesent Biotechnology Co., Ltd. Business Overview
12.17.3 Shaanxi Lesent Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.17.4 Shaanxi Lesent Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.17.5 Shaanxi Lesent Biotechnology Co., Ltd. Recent Developments
12.18 Shaanxi Shuoyang Biotechnology Co., Ltd.
12.18.1 Shaanxi Shuoyang Biotechnology Co., Ltd. Corporation Information
12.18.2 Shaanxi Shuoyang Biotechnology Co., Ltd. Business Overview
12.18.3 Shaanxi Shuoyang Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.18.4 Shaanxi Shuoyang Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.18.5 Shaanxi Shuoyang Biotechnology Co., Ltd. Recent Developments
12.19 Shaanxi Mufan Biotechnology Co., Ltd.
12.19.1 Shaanxi Mufan Biotechnology Co., Ltd. Corporation Information
12.19.2 Shaanxi Mufan Biotechnology Co., Ltd. Business Overview
12.19.3 Shaanxi Mufan Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.19.4 Shaanxi Mufan Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.19.5 Shaanxi Mufan Biotechnology Co., Ltd. Recent Developments
12.20 Xi'an An'Drong Biomedical Technology Co., Ltd.
12.20.1 Xi'an An'Drong Biomedical Technology Co., Ltd. Corporation Information
12.20.2 Xi'an An'Drong Biomedical Technology Co., Ltd. Business Overview
12.20.3 Xi'an An'Drong Biomedical Technology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.20.4 Xi'an An'Drong Biomedical Technology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.20.5 Xi'an An'Drong Biomedical Technology Co., Ltd. Recent Developments
12.21 Shaanxi Guanchen Biotechnology Co., Ltd.
12.21.1 Shaanxi Guanchen Biotechnology Co., Ltd. Corporation Information
12.21.2 Shaanxi Guanchen Biotechnology Co., Ltd. Business Overview
12.21.3 Shaanxi Guanchen Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Product Models, Descriptions and Specifications
12.21.4 Shaanxi Guanchen Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.21.5 Shaanxi Guanchen Biotechnology Co., Ltd. Recent Developments
13 Value Chain and Supply-Chain Analysis
13.1 Bifidobacterium Longum Subsp. Infantis M-63 Industry Chain
13.2 Bifidobacterium Longum Subsp. Infantis M-63 Upstream Materials Analysis
13.2.1 Raw Materials
13.2.2 Key Suppliers Market Share & Risk Assessment
13.3 Bifidobacterium Longum Subsp. Infantis M-63 Integrated Production Analysis
13.3.1 Manufacturing Footprint Analysis
13.3.2 Production Technology Overview
13.3.3 Regional Cost Drivers
13.4 Bifidobacterium Longum Subsp. Infantis M-63 Sales Channels and Distribution Networks
13.4.1 Sales Channels
13.4.2 Distributors
14 Bifidobacterium Longum Subsp. Infantis M-63 Market Dynamics
14.1 Industry Trends and Evolution
14.2 Market Growth Drivers and Emerging Opportunities
14.3 Market Challenges, Risks, and Restraints
15 Key Findings in the Global Bifidobacterium Longum Subsp. Infantis M-63 Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.1.1 Research Programs/Design
16.1.1.2 Market Size Estimation
16.1.1.3 Market Breakdown and Data Triangulation
16.1.2 Data Source
16.1.2.1 Secondary Sources
16.1.2.2 Primary Sources
16.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 7. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales by Region (2020-2025) & (Tons)
Table 8. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales by Region (2026-2031) & (Tons)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Bifidobacterium Longum Subsp. Infantis M-63 Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 11. Global Bifidobacterium Longum Subsp. Infantis M-63 Production by Region (2020-2025) & (Tons)
Table 12. Global Bifidobacterium Longum Subsp. Infantis M-63 Production by Region (2026-2031) & (Tons)
Table 13. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales by Manufacturers (2020-2025) & (Tons)
Table 14. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Share by Manufacturers (2020-2025)
Table 15. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 16. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue Market Share by Manufacturers (2020-2025)
Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 18. Global Bifidobacterium Longum Subsp. Infantis M-63 by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bifidobacterium Longum Subsp. Infantis M-63 as of 2024)
Table 19. Global Bifidobacterium Longum Subsp. Infantis M-63 Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 20. Global Bifidobacterium Longum Subsp. Infantis M-63 Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Ton)
Table 21. Key Manufacturers Bifidobacterium Longum Subsp. Infantis M-63 Manufacturing Base and Headquarters
Table 22. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Concentration Ratio (CR5 and HHI)
Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 25. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales by Type (2020-2025) & (Tons)
Table 26. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales by Type (2026-2031) & (Tons)
Table 27. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue by Type (2020-2025) & (US$ Million)
Table 28. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue by Type (2026-2031) & (US$ Million)
Table 29. Global Bifidobacterium Longum Subsp. Infantis M-63 ASP by Type (2020-2031) & (US$/Ton)
Table 30. Technical Specifications by Key Product Type
Table 31. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales by Application (2020-2025) & (Tons)
Table 32. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales by Application (2026-2031) & (Tons)
Table 33. Bifidobacterium Longum Subsp. Infantis M-63 High-Growth Sectors Demand CAGR (2024-2031)
Table 34. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue by Application (2020-2025) & (US$ Million)
Table 35. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue by Application (2026-2031) & (US$ Million)
Table 36. Global Bifidobacterium Longum Subsp. Infantis M-63 ASP by Application (2020-2031) & (US$/Ton)
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Bifidobacterium Longum Subsp. Infantis M-63 Growth Accelerators and Market Barriers
Table 40. North America Bifidobacterium Longum Subsp. Infantis M-63 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 41. North America Bifidobacterium Longum Subsp. Infantis M-63 Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 42. Europe Bifidobacterium Longum Subsp. Infantis M-63 Growth Accelerators and Market Barriers
Table 43. Europe Bifidobacterium Longum Subsp. Infantis M-63 Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. Europe Bifidobacterium Longum Subsp. Infantis M-63 Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 45. Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 47. Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Growth Accelerators and Market Barriers
Table 48. Southeast Asia Bifidobacterium Longum Subsp. Infantis M-63 Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 49. Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Investment Opportunities and Key Challenges
Table 50. Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 51. Middle East and Africa Bifidobacterium Longum Subsp. Infantis M-63 Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Bifidobacterium Longum Subsp. Infantis M-63 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 53. Mitushi Biopharma Corporation Information
Table 54. Mitushi Biopharma Description and Major Businesses
Table 55. Mitushi Biopharma Product Models, Descriptions and Specifications
Table 56. Mitushi Biopharma Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 57. Mitushi Biopharma Sales Value Proportion by Product in 2024
Table 58. Mitushi Biopharma Sales Value Proportion by Application in 2024
Table 59. Mitushi Biopharma Sales Value Proportion by Geographic Area in 2024
Table 60. Mitushi Biopharma Bifidobacterium Longum Subsp. Infantis M-63 SWOT Analysis
Table 61. Mitushi Biopharma Recent Developments
Table 62. Fengchen Group Corporation Information
Table 63. Fengchen Group Description and Major Businesses
Table 64. Fengchen Group Product Models, Descriptions and Specifications
Table 65. Fengchen Group Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 66. Fengchen Group Sales Value Proportion by Product in 2024
Table 67. Fengchen Group Sales Value Proportion by Application in 2024
Table 68. Fengchen Group Sales Value Proportion by Geographic Area in 2024
Table 69. Fengchen Group Bifidobacterium Longum Subsp. Infantis M-63 SWOT Analysis
Table 70. Fengchen Group Recent Developments
Table 71. Jiangsu Wecare Biotechnology Co., Ltd. Corporation Information
Table 72. Jiangsu Wecare Biotechnology Co., Ltd. Description and Major Businesses
Table 73. Jiangsu Wecare Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 74. Jiangsu Wecare Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 75. Jiangsu Wecare Biotechnology Co., Ltd. Sales Value Proportion by Product in 2024
Table 76. Jiangsu Wecare Biotechnology Co., Ltd. Sales Value Proportion by Application in 2024
Table 77. Jiangsu Wecare Biotechnology Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 78. Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 SWOT Analysis
Table 79. Jiangsu Wecare Biotechnology Co., Ltd. Recent Developments
Table 80. Shenzhen Lefu Biotechnology Co., Ltd. Corporation Information
Table 81. Shenzhen Lefu Biotechnology Co., Ltd. Description and Major Businesses
Table 82. Shenzhen Lefu Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 83. Shenzhen Lefu Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 84. Shenzhen Lefu Biotechnology Co., Ltd. Sales Value Proportion by Product in 2024
Table 85. Shenzhen Lefu Biotechnology Co., Ltd. Sales Value Proportion by Application in 2024
Table 86. Shenzhen Lefu Biotechnology Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 87. Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 SWOT Analysis
Table 88. Shenzhen Lefu Biotechnology Co., Ltd. Recent Developments
Table 89. Hebei Hongtao Bioengineering Co., Ltd. Corporation Information
Table 90. Hebei Hongtao Bioengineering Co., Ltd. Description and Major Businesses
Table 91. Hebei Hongtao Bioengineering Co., Ltd. Product Models, Descriptions and Specifications
Table 92. Hebei Hongtao Bioengineering Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 93. Hebei Hongtao Bioengineering Co., Ltd. Sales Value Proportion by Product in 2024
Table 94. Hebei Hongtao Bioengineering Co., Ltd. Sales Value Proportion by Application in 2024
Table 95. Hebei Hongtao Bioengineering Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 96. Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Longum Subsp. Infantis M-63 SWOT Analysis
Table 97. Hebei Hongtao Bioengineering Co., Ltd. Recent Developments
Table 98. Shandong Junle Biotechnology Co., Ltd. Corporation Information
Table 99. Shandong Junle Biotechnology Co., Ltd. Description and Major Businesses
Table 100. Shandong Junle Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 101. Shandong Junle Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 102. Shandong Junle Biotechnology Co., Ltd. Recent Developments
Table 103. Shandong Xinxiong Biotechnology Co., Ltd. Corporation Information
Table 104. Shandong Xinxiong Biotechnology Co., Ltd. Description and Major Businesses
Table 105. Shandong Xinxiong Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 106. Shandong Xinxiong Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 107. Shandong Xinxiong Biotechnology Co., Ltd. Recent Developments
Table 108. Newgen Biotech Corporation Information
Table 109. Newgen Biotech Description and Major Businesses
Table 110. Newgen Biotech Product Models, Descriptions and Specifications
Table 111. Newgen Biotech Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 112. Newgen Biotech Recent Developments
Table 113. Pharm-Rx Corporation Information
Table 114. Pharm-Rx Description and Major Businesses
Table 115. Pharm-Rx Product Models, Descriptions and Specifications
Table 116. Pharm-Rx Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 117. Pharm-Rx Recent Developments
Table 118. Rajvi Enterprise Corporation Information
Table 119. Rajvi Enterprise Description and Major Businesses
Table 120. Rajvi Enterprise Product Models, Descriptions and Specifications
Table 121. Rajvi Enterprise Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 122. Rajvi Enterprise Recent Developments
Table 123. Shandong Pingao Pharmaceutical Co., Ltd. Corporation Information
Table 124. Shandong Pingao Pharmaceutical Co., Ltd. Description and Major Businesses
Table 125. Shandong Pingao Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 126. Shandong Pingao Pharmaceutical Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 127. Shandong Pingao Pharmaceutical Co., Ltd. Recent Developments
Table 128. Shaanxi Chenming Biotechnology Co., Ltd. Corporation Information
Table 129. Shaanxi Chenming Biotechnology Co., Ltd. Description and Major Businesses
Table 130. Shaanxi Chenming Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 131. Shaanxi Chenming Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 132. Shaanxi Chenming Biotechnology Co., Ltd. Recent Developments
Table 133. Xi'an Minglang Biotechnology Co., Ltd. Corporation Information
Table 134. Xi'an Minglang Biotechnology Co., Ltd. Description and Major Businesses
Table 135. Xi'an Minglang Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 136. Xi'an Minglang Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 137. Xi'an Minglang Biotechnology Co., Ltd. Recent Developments
Table 138. Jiahe Biotechnology (Shanxi) Co., Ltd. Corporation Information
Table 139. Jiahe Biotechnology (Shanxi) Co., Ltd. Description and Major Businesses
Table 140. Jiahe Biotechnology (Shanxi) Co., Ltd. Product Models, Descriptions and Specifications
Table 141. Jiahe Biotechnology (Shanxi) Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 142. Jiahe Biotechnology (Shanxi) Co., Ltd. Recent Developments
Table 143. Shaanxi Ruimao Biotechnology Co., Ltd. Corporation Information
Table 144. Shaanxi Ruimao Biotechnology Co., Ltd. Description and Major Businesses
Table 145. Shaanxi Ruimao Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 146. Shaanxi Ruimao Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 147. Shaanxi Ruimao Biotechnology Co., Ltd. Recent Developments
Table 148. Shaanxi Baohe Biotechnology Co., Ltd. Corporation Information
Table 149. Shaanxi Baohe Biotechnology Co., Ltd. Description and Major Businesses
Table 150. Shaanxi Baohe Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 151. Shaanxi Baohe Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 152. Shaanxi Baohe Biotechnology Co., Ltd. Recent Developments
Table 153. Shaanxi Lesent Biotechnology Co., Ltd. Corporation Information
Table 154. Shaanxi Lesent Biotechnology Co., Ltd. Description and Major Businesses
Table 155. Shaanxi Lesent Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 156. Shaanxi Lesent Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 157. Shaanxi Lesent Biotechnology Co., Ltd. Recent Developments
Table 158. Shaanxi Shuoyang Biotechnology Co., Ltd. Corporation Information
Table 159. Shaanxi Shuoyang Biotechnology Co., Ltd. Description and Major Businesses
Table 160. Shaanxi Shuoyang Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 161. Shaanxi Shuoyang Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 162. Shaanxi Shuoyang Biotechnology Co., Ltd. Recent Developments
Table 163. Shaanxi Mufan Biotechnology Co., Ltd. Corporation Information
Table 164. Shaanxi Mufan Biotechnology Co., Ltd. Description and Major Businesses
Table 165. Shaanxi Mufan Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 166. Shaanxi Mufan Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 167. Shaanxi Mufan Biotechnology Co., Ltd. Recent Developments
Table 168. Xi'an An'Drong Biomedical Technology Co., Ltd. Corporation Information
Table 169. Xi'an An'Drong Biomedical Technology Co., Ltd. Description and Major Businesses
Table 170. Xi'an An'Drong Biomedical Technology Co., Ltd. Product Models, Descriptions and Specifications
Table 171. Xi'an An'Drong Biomedical Technology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 172. Xi'an An'Drong Biomedical Technology Co., Ltd. Recent Developments
Table 173. Shaanxi Guanchen Biotechnology Co., Ltd. Corporation Information
Table 174. Shaanxi Guanchen Biotechnology Co., Ltd. Description and Major Businesses
Table 175. Shaanxi Guanchen Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 176. Shaanxi Guanchen Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 177. Shaanxi Guanchen Biotechnology Co., Ltd. Recent Developments
Table 178. Key Raw Materials Distribution
Table 179. Raw Materials Key Suppliers
Table 180. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 181. Milestones in Production Technology Evolution
Table 182. Distributors List
Table 183. Market Trends and Market Evolution
Table 184. Market Drivers and Opportunities
Table 185. Market Challenges, Risks, and Restraints
Table 186. Research Programs/Design for This Report
Table 187. Key Data Information from Secondary Sources
Table 188. Key Data Information from Primary Sources
List of Figures
Figure 1. Bifidobacterium Longum Subsp. Infantis M-63 Product Picture
Figure 2. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. 0-50 billion CFU/g Product Picture
Figure 4. 50-100 billion CFU/g Product Picture
Figure 5. ＞100 billion CFU/g Product Picture
Figure 6. Global Bifidobacterium Longum Subsp. Infantis M-63 Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Food Additives
Figure 8. Medicines and Supplements
Figure 9. Feed Additives
Figure 10. Others
Figure 11. Bifidobacterium Longum Subsp. Infantis M-63 Report Years Considered
Figure 12. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 14. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue Market Share by Region (2020-2031)
Figure 16. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales (2020-2031) & (Tons)
Figure 17. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales (CAGR) by Region (2020-2031) (Tons)
Figure 18. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Market Share by Region (2020-2031)
Figure 19. Global Bifidobacterium Longum Subsp. Infantis M-63 Capacity, Production and Utilization (2020-2031) & (Tons)
Figure 20. Global Bifidobacterium Longum Subsp. Infantis M-63 Production Trend by Region (2020-2031) (Tons)
Figure 21. Global Bifidobacterium Longum Subsp. Infantis M-63 Production Market Share by Region (2020-2031)
Figure 22. Production Capacity Enablers & Constraints
Figure 23. Bifidobacterium Longum Subsp. Infantis M-63 Production Growth Rate in North America (2020-2031) & (Tons)
Figure 24. Bifidobacterium Longum Subsp. Infantis M-63 Production Growth Rate in Europe (2020-2031) & (Tons)
Figure 25. Bifidobacterium Longum Subsp. Infantis M-63 Production Growth Rate in China (2020-2031) & (Tons)
Figure 26. Bifidobacterium Longum Subsp. Infantis M-63 Production Growth Rate in Japan (2020-2031) & (Tons)
Figure 27. Top 5 and Top 10 Manufacturers Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume Market Share in 2024
Figure 28. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue Market Share Ranking (2024)
Figure 29. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 30. 0-50 billion CFU/g Revenue Market Share by Manufacturer in 2024
Figure 31. 50-100 billion CFU/g Revenue Market Share by Manufacturer in 2024
Figure 32. ＞100 billion CFU/g Revenue Market Share by Manufacturer in 2024
Figure 33. Type Eight Revenue Market Share by Manufacturer in 2024
Figure 34. Type Nine Revenue Market Share by Manufacturer in 2024
Figure 35. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Market Share by Type (2020-2031)
Figure 36. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue Market Share by Type (2020-2031)
Figure 37. Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Market Share by Application (2020-2031)
Figure 38. Global Bifidobacterium Longum Subsp. Infantis M-63 Revenue Market Share by Application (2020-2031)
Figure 39. North America Bifidobacterium Longum Subsp. Infantis M-63 Sales YoY (2020-2031) & (Tons)
Figure 40. North America Bifidobacterium Longum Subsp. Infantis M-63 Revenue YoY (2020-2031) & (US$ Million)
Figure 41. North America Top 5 Manufacturers Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) in 2024
Figure 42. North America Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume (Tons) by Type (2020- 2031)
Figure 43. North America Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 44. North America Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume (Tons) by Application (2020-2031)
Figure 45. North America Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) by Application (2020-2031)
Figure 46. US Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 47. Canada Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 48. Mexico Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 49. Europe Bifidobacterium Longum Subsp. Infantis M-63 Sales YoY (2020-2031) & (Tons)
Figure 50. Europe Bifidobacterium Longum Subsp. Infantis M-63 Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Europe Top 5 Manufacturers Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) in 2024
Figure 52. Europe Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume (Tons) by Type (2020-2031)
Figure 53. Europe Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) by Type (2020-2031)
Figure 54. Europe Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume (Tons) by Application (2020-2031)
Figure 55. Europe Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) by Application (2020-2031)
Figure 56. Germany Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 57. France Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 58. U.K. Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 59. Italy Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 60. Russia Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 61. Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Sales YoY (2020-2031) & (Tons)
Figure 62. Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Asia-Pacific Top 8 Manufacturers Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) in 2024
Figure 64. Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume (Tons) by Type (2020- 2031)
Figure 65. Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 66. Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume (Tons) by Application (2020-2031)
Figure 67. Asia-Pacific Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) by Application (2020-2031)
Figure 68. Indonesia Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 69. Japan Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 70. South Korea Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 71. China Taiwan Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 72. India Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2031) & (US$ Million)
Figure 73. Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Sales YoY (2020-2031) & (Tons)
Figure 74. Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Revenue YoY (2020-2031) & (US$ Million)
Figure 75. Central and South America Top 5 Manufacturers Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) in 2024
Figure 76. Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume (Tons) by Type (2021-2031)
Figure 77. Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) by Type (2020-2031)
Figure 78. Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume (Tons) by Application (2020-2031)
Figure 79. Central and South America Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) by Application (2020-2031)
Figure 80. Brazil Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2025) & (US$ Million)
Figure 81. Argentina Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2025) & (US$ Million)
Figure 82. Middle East, and Africa Bifidobacterium Longum Subsp. Infantis M-63 Sales YoY (2020-2031) & (Tons)
Figure 83. Middle East and Africa Bifidobacterium Longum Subsp. Infantis M-63 Revenue YoY (2020-2031) & (US$ Million)
Figure 84. Middle East and Africa Top 5 Manufacturers Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) in 2024
Figure 85. Middle East and Africa Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume (Tons) by Type (2021-2031)
Figure 86. South America Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) by Type (2020-2031)
Figure 87. Middle East and Africa Bifidobacterium Longum Subsp. Infantis M-63 Sales Volume (Tons) by Application (2020-2031)
Figure 88. Middle East and Africa Bifidobacterium Longum Subsp. Infantis M-63 Sales Revenue (US$ Million) by Application (2020-2031)
Figure 89. GCC Countries Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2025) & (US$ Million)
Figure 90. Turkey Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2025) & (US$ Million)
Figure 91. Egypt Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2025) & (US$ Million)
Figure 92. South Africa Bifidobacterium Longum Subsp. Infantis M-63 Revenue (2020-2025) & (US$ Million)
Figure 93. Bifidobacterium Longum Subsp. Infantis M-63 Industry Chain Mapping
Figure 94. Regional Bifidobacterium Longum Subsp. Infantis M-63 Manufacturing Base Distribution (%)
Figure 95. Bifidobacterium Longum Subsp. Infantis M-63 Production Process
Figure 96. Regional Bifidobacterium Longum Subsp. Infantis M-63 Production Cost Structure
Figure 97. Channels of Distribution (Direct Vs Distribution)
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 6.2% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
What is the annual compound growth rate of the global Bifidobacterium Longum Subsp. Infantis M-63 market size from 2025 to 2031?
Which companies rank high in the global Bifidobacterium Longum Subsp. Infantis M-63 market?
What was the global market size of Bifidobacterium Longum Subsp. Infantis M-63 in 2025?
What was the global market size of Bifidobacterium Longum Subsp. Infantis M-63 in 2031?
Related Reports
Global Bifidobacterium Longum Subsp. Infantis M-63 Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Bifidobacterium Longum Subsp. Infantis M-63 market is projected to grow from US$ 47.19 million in 2025 to US$ 71.49 million by 2032, at a CAGR of 6.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-26
Pages: 200
USD 4900.00
(Single User License)
Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Bifidobacterium Longum Subsp. Infantis M-63 market size was US$ 47.19 million in 2025 and is forecast to reach a readjusted size of US$ 71.49 million by 2032 with a CAGR of 6.2% during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 115
USD 4250.00
(Single User License)
Bifidobacterium Longum Subsp. Infantis M-63- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Bifidobacterium Longum Subsp. Infantis M-63 was estimated to be worth US$ 47.19 million in 2025 and is projected to reach US$ 71.49 million, growing at a CAGR of 6.2% from 2026 to 2032.
Published Date: 2026-01-09
Pages: 154
USD 3950.00
(Single User License)
Global Bifidobacterium Longum Subsp. Infantis M-63 Market Research Report 2026
The global Bifidobacterium Longum Subsp. Infantis M-63 market was valued at US$ 47.19 million in 2025 and is anticipated to reach US$ 71.49 million by 2032, at a CAGR of 6.2% from 2026 to 2032.
Published Date: 2026-01-09
Pages: 163
USD 2900.00
(Single User License)
Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Bifidobacterium Longum Subsp. Infantis M-63 market size was US$ 44.7 million in 2024 and is forecast to a readjusted size of US$ 67.7 million by 2031 with a CAGR of 6.2% during the forecast period 2025-2031.
Published Date: 2025-03-10
Pages: 112
USD 4250.00
(Single User License)
Bifidobacterium Longum Subsp. Infantis M-63 - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Bifidobacterium Longum Subsp. Infantis M-63 was estimated to be worth US$ 44.7 million in 2024 and is forecast to a readjusted size of US$ 67.7 million by 2031 with a CAGR of 6.2% during the forecast period 2025-2031.
Published Date: 2025-03-10
Pages: 159
USD 3950.00
(Single User License)
Global Bifidobacterium Longum Subsp. Infantis M-63 Market Research Report 2025
The global market for Bifidobacterium Longum Subsp. Infantis M-63 was valued at US$ 44.7 million in the year 2024 and is projected to reach a revised size of US$ 67.7 million by 2031, growing at a CAGR of 6.2% during the forecast period.
Published Date: 2025-03-10
Pages: 120
USD 2900.00
(Single User License)
Global and United States Bifidobacterium Longum Subsp. Infantis M-63 Market Report & Forecast 2024-2030
Bifidobacterium Longum Subsp. Infantis M-63 is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published Date: 2024-09-11
Pages: 172
USD 4350.00
(Single User License)
Global Bifidobacterium Longum Subsp. Infantis M-63 Market Insights, Forecast to 2030
Bifidobacterium Longum Subsp. Infantis M-63 is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published Date: 2024-09-11
Pages: 193
USD 4900.00
(Single User License)
Global Bifidobacterium Longum Subsp. Infantis M-63 Market Research Report 2024
Bifidobacterium Longum Subsp. Infantis M-63 is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published Date: 2024-09-11
Pages: 120
USD 2900.00
(Single User License)
Global Bifidobacterium Longum Subsp. Infantis M-63 Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Bifidobacterium Longum Subsp. Infantis M-63 market is projected to grow from US$ 47.19 million in 2025 to US$ 71.49 million by 2032, at a CAGR of 6.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-26
Pages: 200
USD 4900.00 (Single User License)Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Bifidobacterium Longum Subsp. Infantis M-63 market size was US$ 47.19 million in 2025 and is forecast to reach a readjusted size of US$ 71.49 million by 2032 with a CAGR of 6.2% during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 115
USD 4250.00 (Single User License)Bifidobacterium Longum Subsp. Infantis M-63- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Bifidobacterium Longum Subsp. Infantis M-63 was estimated to be worth US$ 47.19 million in 2025 and is projected to reach US$ 71.49 million, growing at a CAGR of 6.2% from 2026 to 2032.
Published: 2026-01-09
Pages: 154
USD 3950.00 (Single User License)Global Bifidobacterium Longum Subsp. Infantis M-63 Market Research Report 2026
The global Bifidobacterium Longum Subsp. Infantis M-63 market was valued at US$ 47.19 million in 2025 and is anticipated to reach US$ 71.49 million by 2032, at a CAGR of 6.2% from 2026 to 2032.
Published: 2026-01-09
Pages: 163
USD 2900.00 (Single User License)Global Bifidobacterium Longum Subsp. Infantis M-63 Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Bifidobacterium Longum Subsp. Infantis M-63 market size was US$ 44.7 million in 2024 and is forecast to a readjusted size of US$ 67.7 million by 2031 with a CAGR of 6.2% during the forecast period 2025-2031.
Published: 2025-03-10
Pages: 112
USD 4250.00 (Single User License)Bifidobacterium Longum Subsp. Infantis M-63 - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Bifidobacterium Longum Subsp. Infantis M-63 was estimated to be worth US$ 44.7 million in 2024 and is forecast to a readjusted size of US$ 67.7 million by 2031 with a CAGR of 6.2% during the forecast period 2025-2031.
Published: 2025-03-10
Pages: 159
USD 3950.00 (Single User License)Global Bifidobacterium Longum Subsp. Infantis M-63 Market Research Report 2025
The global market for Bifidobacterium Longum Subsp. Infantis M-63 was valued at US$ 44.7 million in the year 2024 and is projected to reach a revised size of US$ 67.7 million by 2031, growing at a CAGR of 6.2% during the forecast period.
Published: 2025-03-10
Pages: 120
USD 2900.00 (Single User License)Global and United States Bifidobacterium Longum Subsp. Infantis M-63 Market Report & Forecast 2024-2030
Bifidobacterium Longum Subsp. Infantis M-63 is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published: 2024-09-11
Pages: 172
USD 4350.00 (Single User License)Global Bifidobacterium Longum Subsp. Infantis M-63 Market Insights, Forecast to 2030
Bifidobacterium Longum Subsp. Infantis M-63 is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published: 2024-09-11
Pages: 193
USD 4900.00 (Single User License)Global Bifidobacterium Longum Subsp. Infantis M-63 Market Research Report 2024
Bifidobacterium Longum Subsp. Infantis M-63 is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published: 2024-09-11
Pages: 120
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now